[HTML][HTML] Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes
MS Ahmad, M Braoudaki, H Patel… - Frontiers in …, 2023 - nchr.elsevierpure.com
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes
MS Ahmad, M Braoudaki, H Patel - Glycans: Molecules at the …, 2024 - books.google.com
1 Background Colorectal cancer (CRC) has been referred to as the fourth most diagnosed
cancer worldwide and the third leading cause of patient mortality in humans (1) …
cancer worldwide and the third leading cause of patient mortality in humans (1) …
Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes
MS Ahmad, M Braoudaki, H Patel… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes.
MS Ahmad, M Braoudaki, H Patel, I Ahmad… - Frontiers in …, 2023 - europepmc.org
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes
MS Ahmad, M Braoudaki, H Patel, I Ahmad… - Frontiers in …, 2023 - uhra.herts.ac.uk
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
[HTML][HTML] Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes
MS Ahmad, M Braoudaki, H Patel, I Ahmad… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes
MS Ahmad, M Braoudaki, H Patel… - Frontiers in …, 2023 - researchprofiles.herts.ac.uk
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …